Global CRISPR Gene Detection and Diagnostic Market Assessment 2023-2027: Focus on Applications, Organisms, and Key Players in the Industry
January 16, 2024 04:28 ET
|
Research and Markets
Dublin, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The "CRISPR Gene Detection and Diagnostic Markets by Research, Clinical Lab, Consumer, Public Service & Other with Executive and Consultant Guides, 2023...
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
January 07, 2024 11:00 ET
|
Caribou Biosciences, Inc.
-- Tim Kelly to lead Caribou’s technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate...
Tome Biosciences Acquires Replace Therapeutics
January 02, 2024 09:00 ET
|
Tome Biosciences
Tome acquires Replace Therapeutics.
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
December 12, 2023 16:02 ET
|
Caribou Biosciences, Inc.
-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial...
Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform
December 12, 2023 07:57 ET
|
Tome Biosciences
Tome Biosciences launches with over $200 million in funding to advance programmable genomic integration (PGI).
Global Enzymatic DNA Synthesis Market Analysis, Trends and Forecasts to 2028 - Opportunities in CRISPR-Cas9 Integration and Cell-Free Synthetic Biology
December 12, 2023 05:23 ET
|
Research and Markets
Dublin, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The "Global Enzymatic DNA Synthesis Market: Analysis By Product Type (DNA Library Synthesis and Custom DNA Synthesis), By Technology (PCR, CRISPR, SOLA and...
Epic Bio to Present at the Upcoming CRISPR2.0 Conference
November 21, 2023 12:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
FDA Grants Orphan Drug Designation to EPI-321, Epic Bio's Novel Genetic Medicine Candidate for Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
November 16, 2023 06:00 ET
|
Epic Bio
- Potential one-time therapy for the treatment of FSHD includes a novel non-cutting dCas protein delivered via a single AAV - - EPI-321 is the only therapy designed to target the epigenetic root...
Genome Editing Market revenue to hit USD 69.6 Billion by 2036, says Research Nester
November 14, 2023 05:30 ET
|
Research Nester
New York, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The global genome editing market size is slated to expand at ~21.1% CAGR between 2024 and 2036. The market is poised to garner a revenue of USD 69.6...
Epic Bio to Participate in Upcoming Investor Conference
November 07, 2023 06:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...